ORMP - Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
- Oramed Pharmaceuticals ( NASDAQ: ORMP ), a clinical-stage pharma focused on diabetes and liver diseases announced on Thursday that despite the challenges in enrollment, the company plans to share data from its Phase 1 trial for oral COVID-19 shot Oravax in 2Q 2022.
- Issuing a letter to shareholders, Oramed ( ORMP ) Chief Executive Nadav Kidron noted that the company has introduced an additional clinical site amid slower than anticipated enrollment.
- Oramed ( ORMP ) has completed the enrollment and dosing in Cohort A with no safety issues so far. While topline data for Cohort A are expected in this quarter.
- Plans are underway to achieve the enrollment target for the Cohort B within this quarter with data anticipated in 4Q 2022.
- Recording $169M in cash and Investments, Oramed ( ORMP ) said its cash runway would be adequate to complete the pivotal Phase 3 trials for ORMD-0801 towards potential FDA approval of the oral insulin candidate.
- In December, Oramed ( ORMP ) announced that its subsidiary, Oravax Medical signed an agreement with a Vietnam-based company to sell its oral COVID-19 vaccine in Southeast Asia.
For further details see:
Oramed to report early-stage trial data for oral COVID-19 shot in 3Q